NCT07165015View on ClinicalTrials.gov

A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 18, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Renal ImpairmentHealthyRenal InsufficiencyEnd Stage Renal Disease (ESRD)

Interventions

DRUG

LY3537031

Administered SC

Trial Locations (4)

32808

RECRUITING

Omega Research Orlando LLC, Orlando

32809

NOT_YET_RECRUITING

Orlando Clinical Research Center, Orlando

46202-5188

NOT_YET_RECRUITING

Indiana University School of Medicine, Indianapolis

Unknown

NOT_YET_RECRUITING

New Zealand Clinical Research Christchurch, Christchurch

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT07165015 - A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment | Biotech Hunter | Biotech Hunter